Background: Lactation induction in transgender women is a clinical and research priority in the field of breastfeeding medicine. To date, there are four case reports detailing successful induced lactation in transgender patients who wished to breastfeed. The Academy of Breast Feeding Medicine does not formally recommend a specific medication regimen for transgender patients due to lack of high-quality research. Case Presentation: A 50-year-old transgender woman with a hypercoagulable disorder who was able to lactate and breastfeed with novel hormone regimen management at a gender care clinic. Her baseline hormone treatment was an estradiol 0.3 mg transdermal patch every 72 hours and micronized progesterone 200 mg daily. Results: Within four weeks of initiating a modified hormone regimen (estradiol 0.4 mg patch every 72 hours, progesterone 300 mg daily, metoclopramide 10 mg three times daily), the patient was lactating spontaneously. On multiple occasions, she breastfed and expressed up to 30 mL of milk through pumping. Conclusion: This report offers a new effective hormone regimen for transgender patients who wish to lactate and cannot access domperidone-the galactagogue used in previous case reports. It also provides a review of previously published case reports on this subject. Future research in this field should prioritize cohort studies of transgender patients who desire lactation to further assess patient attitudes, experiences, and outcomes.

Background: Transfeminine individuals are capable of developing breast tissue that is indistinguishable from cis-females, allowing them to breastfeed effectively. Breastfeeding affords known health benefits for both members of a lactating individual–infant dyad and supporting this experience for transfeminine individuals fosters reproductive equity. Objective: This study assessed experiences, attitudes, and knowledge regarding breastfeeding and lactation among a group of transfeminine individuals receiving hormone therapy within a specialized gender care clinic. Methods: Transfeminine individuals on estrogen therapy who were part of the Duke Research for Equitable Access to Medicine (DREAM) Registry were invited to complete a 15-question online survey about experiences, goals, attitudes, and knowledge regarding lactation and breastfeeding. Results: A total of 71 out of 130 eligible DREAM individuals completed the survey (54.6%). No survey participants had breastfed and three (4.2%) had experienced lactation. One in four participants designated lactation a health care goal. Four out of five participants reported it was important, most commonly to affirm their gender identity ( n = 41, 57.7%) and/or to bring their breasts to full maturity ( n = 36, 50.7%). One in eight participants designated breastfeeding as a health care goal. Four out of five participants reported it was important, most commonly for parent–child bonding ( n = 34, 47.9%) and/or health/nutritional benefits to the newborn ( n = 34, 47.9%). Conclusion: Transfeminine individuals may be interested in experiencing lactation for multifaceted reasons, including goals for parent–infant feeding (breastfeeding-dyad bonding and breast milk health benefits) and for their gender transition (affirming gender and breast maturity). Future community-engaged research is warranted to inform both clinical practice and lactation protocols for transfeminine individuals hoping to breastfeed.

Transgender and gender diverse (TGD) populations are often excluded from research or inappropriately grouped with other gender modalities despite significant disparities in health and health care. According to models of community-engaged research, involving TGD community members in establishing research priorities can improve the relevance and impact of research for this population. The purpose of this study was to clarify community priorities for research relevant to TGD populations. Forty-five individuals participated across five asynchronous online focus groups. Participants discussed topics chosen in collaboration with a community research advisory board, including gender-affirming hormone therapy. Rapid qualitative analysis was used to identify salient themes. Research priorities voiced across all represented gender identities were: (1) Longitudinal, prospective research on long-term effects of gender-affirming hormone therapy, (2) Standardized training for providers and researchers, (3) Implementation research on methods to educate the public and reduce discrimination, and (4) Basic research on the biological, historical, and social underpinnings of gender identity. This study provides insight into clinical priorities for TGD populations. Findings highlight a need for basic science research to better understand the underpinnings of gender identity, longitudinal studies to investigate long-term effects of hormone therapy, and education for the public on gender diversity to combat discrimination.

Background: The use of estrogen-based gender-affirming hormone therapy (E-GAHT) has been associated with an increased risk of venous thromboembolism (VTE), but much of the evidence originates from data on cisgender women and from cohorts of transgender and gender diverse (TGD) individuals treated with older estrogen or estrogen/progesterone preparations, often at higher doses. Data on VTE risks associated with more modern E-GAHT regimens in TGD populations are scarce. Methods: A retrospective cohort study of adult TGD individuals who received E-GAHT within the Duke University Health System between January 1996 and June 2025 was conducted. The Duke Enterprise Data Unified Content Explorer (DEDUCE), a Duke electronic medical record search tool, was utilized to identify a cohort of TGD individuals who were prescribed E-GAHT. From this cohort, individuals who experienced a VTE during E-GAHT exposure were identified. Demographic characteristics and comorbidities were compared between the overall study cohort and those who experienced VTE using the SlicerDicer tool within Epic, supplemented by manual chart review. Results: Among 1173 adult TGD individuals prescribed E-GAHT, 16 (1.4%) experienced a VTE. Of these, 11 (68.8%) experienced a pulmonary embolism (PE with/without deep vein thrombosis [DVT]) and five (31.3%) experienced a DVT alone. Among the 16 patients with VTE, six (37.5%) had a transient surgical risk factor prior to VTE, three (18%) had significant non-surgical risk factors, and one (6%) had cancer. The remaining six (37.5%) patients experienced an unprovoked VTE. Patients with VTE were significantly older than the general population of TGD adults and were significantly more likely to experience hypertension, hyperlipidemia, and type 2 diabetes mellitus, compared to TGD patients without VTE. Conclusions: In this retrospective cohort, the proportion of TGD individuals on E-GAHT with VTE was lower than previously reported in the literature. Most events occurred in the presence of other established risk factors, suggesting that E-GAHT itself may confer a lower VTE risk than previously assumed. Larger prospective studies that evaluate both estrogen-specific and patient-specific risk factors are needed to clarify VTE risk in this population.